Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inhibitor of DNA binding protein 1 (ID1) is a member of the helix-loop-helix (HLH) family of transcription factors that lack a DNA-binding basic domain and function as dominant-negative regulators of other basic HLH transcription factors by forming inactive heterodimers. ID1 plays a key role in regulating cell proliferation, differentiation, cell cycle progression, and maintenance of stem cell characteristics by inhibiting the transcriptional activity of E proteins and related factors. ID1 is overexpressed in a wide range of human cancers, promoting tumorigenesis, metastasis, stemness, angiogenesis, chemoresistance, and radioresistance, and has therefore emerged as a potential therapeutic target and biomarker in oncology. Dysregulation of ID1 also impacts normal biological processes, especially hematopoiesis and stem cell homeostasis
Dominant-negative inhibition of bHLH transcription factor-mediated transcription, Modulation of pathways driving cell differentiation and proliferation, Promotion of chemoresistance and radioresistance, Stimulation of angiogenesis and EMT
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inhibitor of DNA binding protein 1 (ID1).